A PYMNTS Company

The Pharmaceutical Inquiry: Anything to Report?

BY | November 11, 2008

This article is part of a Chronicle. See more from this Chronicle Sean-Paul Brankin, Nov 12, 2008 One reaction to the pharmaceuticals sector inquiry, particularly from the originator side of…

This article is part of a Chronicle. See more from this Chronicle

Sean-Paul Brankin, Nov 12, 2008

One reaction to the pharmaceuticals sector inquiry, particularly from the originator side of the industry, has been to question the need for the investigation. What is certain is that the Commission has set itself a challenging task. It has chosen to investigate a number of competition law issues that are likely to pose substantial legal and evidential difficulties. However, the sector, and originat

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.197.231.211

Please verify email or join us to access premium content!